Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 650x80px
Document › Details

Qiagen N.V.. (8/8/11). "Press Release: Qiagen Opens Taiwan Subsidiary to Further Expand Presence in Asia. Qiagen Establishes Direct Presence in Taiwan, Opening a Key Market to Accelerate Growth". Shanghai & Taipei.

Region Region Taipei
  Country Taiwan
Organisations Organisation Qiagen Taiwan Co., Ltd.
  Group Qiagen (Group)
  Organisation 2 Netherlands (govt)
Products Product sample preparation (technology)
  Product 2 molecular diagnostics
Person Person Shi, Victor (Qiagen Asia 200702)

> New Taiwan subsidiary strengthens QIAGEN's capabilities to serve customers in Asian region

> New office corroborates Company's strategy to expand its geographic presence

QIAGEN today officially opened its new subsidiary in Taiwan, QIAGEN Taiwan Co., Ltd., and began direct sales in the market. To mark the event, QIAGEN held an inauguration ceremony at the Sheraton Hotel, Taipei, attended by 100 distinguished guests, including local government officials, prominent key opinion leaders and customers.

Establishing the subsidiary will complement QIAGEN's close partnerships and strong network with distributors and selected customers across Taiwan. QIAGEN expects the direct presence to further advance its strong position in the rapidly growing, dynamic Taiwan market and to add momentum to QIAGEN's expansion strategy in Asia. The new subsidiary, based in Taipei, has 17 employees.

"We are pleased to see that QIAGEN is taking additional steps to contribute to and support the high quality of science and research being done in Taiwan," said Mr. Hans Fortuin, Representative of the Netherlands Trade and Investment Office. "QIAGEN's expansion into Asia, as bolstered by its direct entry into India earlier this year, is a strong indicator of the constantly growing importance of the Asian region to European companies and the European economy in general." Taiwan's bioresearch market reached a value of US $35 million in 2009 and is projected to continue to grow rapidly in the future. Together with 170 local academic institutions, Taiwan's life sciences R&D and pharmaceutical companies are driving the development of the market and the need for sample and assay technologies. Cancer biomarker research in medical and pharmaceutical R&D is one example of this emerging need. QIAGEN's diverse product portfolio is well positioned to address customers' growing demand by providing highly sensitive, rapid tests producing reliable results for detection of certain gene mutations.

"Geographic expansion is a cornerstone of our corporate strategy. We are always looking for opportunities to expand our presence in potential markets. QIAGEN's new Taiwan subsidiary is a strategic step in further enlarging our commitment to serving customers in Asia, our fastest-growing market. Our business has grown dramatically since we entered China in 2005, and earlier this year we also established a direct presence in India," said Dr. Victor Shi, QIAGEN Asia Pacific President. "Adding a local team and infrastructure in Taiwan will give us more access and help us to provide better support to our local customers, especially in academic research and pharmaceutical drug development."

Since 2005, QIAGEN has expanded to 13 offices with over 500 employees across Asia. In 2010, revenues from Asia, not including Japan, represented approximately 12% of QIAGEN sales.


QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated bio-molecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as a "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics. QIAGEN employs nearly 3,600 people in over 30 locations worldwide. Further information about QIAGEN can be found at

Record changed: 2019-06-09


Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for Qiagen (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

» top